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Abstract. 
 
The yeast vacuolar protein aminopeptidase I 
(API) is synthesized as a cytosolic precursor that is 
transported to the vacuole by a nonclassical targeting 
mechanism. Recent genetic studies indicate that the 
biosynthetic pathway that transports API uses many of 
the same molecular components as the degradative 
autophagy pathway. This overlap coupled with both in 
vitro and in vivo analysis of API import suggested that, 
like autophagy, API transport is vesicular. Subcellular 
fractionation experiments demonstrate that API pre-
cursor (prAPI) initially enters a nonvacuolar cytosolic 
compartment. In addition, subvacuolar vesicles con-
taining prAPI were purified from a mutant strain defec-
tive in breakdown of autophagosomes, further indicat-
ing that prAPI enters the vacuole inside a vesicle. The 
purified subvacuolar vesicles do not appear to contain 
vacuolar marker proteins. Immunogold EM confirms 
that prAPI is localized in cytosolic and in subvacuolar 
vesicles in a mutant strain defective in autophagic body 
degradation. These data suggest that cytosolic vesicles 
containing prAPI fuse with the vacuole to release a 
membrane-bounded intermediate compartment that is 
subsequently broken down, allowing API maturation.
 
T
 
he
 
 yeast vacuole plays a key role in cellular protein
metabolism. During periods of nitrogen starvation,
amino acid supplies are maintained by protein deg-
radation reactions that take place in this organelle (Klion-
sky et al., 1990; Hilt and Wolf, 1992). Accordingly, the
vacuole contains numerous hydrolytic enzymes, compart-
mentalized to prevent nonspecific cellular damage. Sub-
strate proteins are delivered to the vacuole from the cyto-
sol by autophagy (Takeshige et al., 1992; Noda et al.,
1995), and from the cell surface by endocytosis (Riezman,
1993). Precise subcellular transport reactions are neces-
sary to ensure both the faithful compartmentalization of
hydrolytic enzymes and the recognition and timely deliv-
ery of protein substrates for degradation. The majority of
vacuolar hydrolases are delivered to the organelle via the
secretory pathway (Conibear and Stevens, 1995; Stack et al.,
1995). Aminopeptidase I (API)
 
1
 
, however, does not use
the secretory system and is instead targeted by a nonclassi-
cal pathway from the cytoplasm to the vacuole (Klionsky
et al., 1992).
API is synthesized as a cytosolic precursor containing an
amino-terminal propeptide that mediates its vacuolar de-
livery (Segui-Real et al., 1995; Oda et al., 1996). The pro-
region consists of two predicted 
 
a
 
 helices separated by a
proline residue. The first helix is amphipathic and directs
the binding of API to a target membrane (Oda et al.,
1996). Upon arrival in the vacuolar lumen, the proregion
is cleaved in a proteinase B (PrB)–dependent reaction
(Klionsky et al., 1992). Thus, maturation of API is a con-
venient marker for correct vacuolar delivery.
Two lines of evidence suggest that API transport may be
a vesicular event. First, analysis of cytoplasm to vacuole
targeting mutants (
 
cvt
 
; Harding et al., 1995) indicates that
there is substantial overlap between genes involved in API
transport and those required for autophagy (Harding et al.,
1996; Scott et al., 1996). In addition, phenotypic examina-
tion of 
 
cvt
 
 and autophagy mutants (
 
apg
 
, 
 
aut
 
) revealed that
the majority of these mutants are both autophagy defec-
tive and accumulate API precursor (prAPI) (Harding et al.,
1996; Scott et al., 1996). The 
 
apg
 
 mutants (Tsukada and
Ohsumi, 1993) and, presumably, 
 
aut
 
 mutants (Thumm et al.,
1994) are defective in macroautophagy, a process by which
cytosolic proteins and cytoplasmic organelles are engulfed
by double-membraned vesicles and delivered to the vacu-
ole for degradation (Takeshige et al., 1992; Baba et al.,
1994).
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The second indication that API transport is vesicular
comes from recent analysis of the biogenesis of this pro-
tein. These studies indicate that prAPI is transported as a
732-kD dodecamer (Kim et al., 1997). Since this complex
is much too large to penetrate a typical translocation chan-
nel, and large porelike structures cannot be present on an
energetically active membrane such as the vacuole, API
must be transported by a vesicular mechanism.
The degree to which the Cvt pathway is analogous to
bulk macroautophagy remains to be determined. There
are several fundamental differences between these two
pathways. API transport is a specific biosynthetic event
that is constitutive, occurring even under nutrient-rich
conditions (Klionsky et al., 1992; Scott et al., 1996). Bulk
autophagy is nonselective, degradative, and only detect-
able during starvation for nutrients such as nitrogen or
carbon (Takeshige et al., 1992). Also, prAPI has a half-
time for vacuolar delivery of 30–45 min (Klionsky et al.,
1992), while the half-time for delivery of cytosolic proteins
by macroautophagy is at least 12 h when induced by nitro-
gen starvation (Scott et al., 1996). One possible model that
accommodates these differences is that the Cvt pathway
uses essentially the same molecular mechanism as mac-
roautophagy to deliver API to the vacuole. The transport
of API could be made specific, rapid, and constitutive if
API is concentrated into vesicles by a receptor-mediated
mechanism, and the constitutive level of autophagic vesi-
cle formation is sufficient for delivery of API during expo-
sure to various nutrient conditions.
To provide direct evidence that API in fact uses a vesic-
ular mechanism for vacuolar delivery, we have examined
the API transport process biochemically and morphologi-
cally. We have identified two yeast mutants that trap
prAPI inside a vesicular compartment and used one of
these mutant strains to purify an API transport intermedi-
ate. In addition, these data are supported by immuno-EM
images demonstrating that API is concentrated in vesicles
during transport to the vacuole.
 
Materials and Methods
 
Strains and Media
 
Saccharomyces cerevisiae
 
 strains used in this study were: JSR18
 
D
 
1 
 
MAT
 
a
 
vps18
 
D
 
1::TRP1 leu2-3,112 ura3-52 his3-
 
D
 
200 trp1
 
D
 
901 lys2-801 suc2-
 
D
 
9
 
with a plasmid bearing a temperature-sensitive allele of 
 
vps18
 
, pJSR9
(Robinson et al., 1991); SEY6210 
 
MAT
 
a
 
 
 
leu2-3,112 ura3-52 his3-
 
D
 
200
trp1-
 
D
 
901 lys2-801 suc2-
 
D
 
9 GAL
 
 (Robinson et al., 1988); SEY6211 
 
MAT
 
a
 
leu2-3,112 ura3-52 his3-
 
D
 
200 trp1-
 
D
 
901 ade2-101 suc2-
 
D
 
9 GAL
 
 (Robinson
et al., 1988); THY32 
 
cvt17-1
 
 derivative of SEY6211 (Harding et al., 1995,
1996); and DYY101 
 
MAT
 
a
 
 
 
leu2,3-112 ura3-52 his3-
 
D
 
200 trp1-
 
D
 
901 ade2-
101 suc2-
 
D
 
9 GAL ape1
 
D
 
::LEU2
 
 with a single copy plasmid containing the
P22L API construct (Oda et al., 1996). Unless otherwise indicated, cells
were grown in synthetic minimal medium (SMD; 0.067% yeast nitrogen
base, 2% glucose, and auxotrophic amino acids and vitamins as needed).
Synthetic minimal medium without amino acids or ammonium sulfate
containing 2% glucose (SD-N) was used for nitrogen starvation experi-
ments, and YPD (containing 1% yeast extract, 2% peptone, and 2% glu-
cose) was used for cell growth before immuno-EM.
 
Reagents
 
Gold-conjugated goat anti–rabbit IgG was from Biocell (Cardiff, UK). LR
white resin was from London Resin (Hampshire, UK). Optiprep was from
Accurate Chemical and Scientific Corp. (Westbury, NY); Oxalyticase
from Enzogenetics (Corvallis, OR); Expre
 
35
 
S
 
35
 
S was from Dupont-New
England Nuclear Research Products (Boston, MA); proteinase K and Pe-
fabloc were from Boehringer Mannheim Biochemicals (Indianapolis, IN);
SYPRO orange was from BioRad Laboratories (Hercules, CA); and all
other reagents were from Sigma Chemical Co. (St. Louis, MO). Antise-
rum against peptides in the mature region of API (Klionsky et al., 1992),
API propeptide (Harding et al., 1995), carboxypeptidase Y (CPY) and
proteinase A (PrA) (Klionsky et al., 1988), and alkaline phosphatase (ALP)
(Scott et al., 1996) were as described previously. The following antisera
were generously supplied as indicated: phosphoglycerate kinase (PGK) (J.
Thorner, Department of Biochemistry, University of California, Berke-
ley), Sec13p (C. Barlow, Dartmouth Medical School, Hanover, NH),
Kex2p (G. Payne, Department of Biological Chemistry, University of Cal-
ifornia, Los Angeles), and Sec61p (R. Schekman, Department of Molecu-
lar and Cellular Biology, University of California, Berkeley).
 
Pulse-Chase Analysis and Immunoprecipitation
 
For whole cell labeling experiments, yeast strains were grown to 1 OD
 
600
 
/ml
in SMD. Cells were harvested and labeled with 100 
 
m
 
Ci/ml Expre
 
35
 
S
 
35
 
S in
SMD at a cell density of 100 OD
 
600
 
/ml for 5 min. Cold cysteine and me-
thionine were added to 2 mM and 1 mM, respectively. The labeled cells
were chased at a cell density of 1 OD
 
600
 
/ml in SMD for the indicated
times. Where indicated, SD-N was used for chase reactions. Spheroplast
labeling was performed as described (Scott and Klionsky, 1995). Samples
were immunoprecipitated as described (Klionsky et al., 1992).
 
Differential Lysis Fractionation
 
Fractionation experiments were performed using previously described
methods based on differential osmotic lysis (Harding et al., 1995; Oda et al.,
1996). Spheroplasts were permeabilized in 200 mM sorbitol, 20 mM K-Pipes,
pH 6.8 (PS200), and soluble (S
 
200
 
) and organelle-containing (P
 
200
 
) frac-
tions were collected by centrifugation at 5,000 
 
g
 
 for 5 min. This treatment
consistently releases 
 
.
 
95% of the cytosolic marker PGK into the superna-
tant while maintaining 
 
z
 
70% of the vacuole lumen marker PrA in the pel-
let fraction (Harding et al., 1995, 1996; Oda et al., 1996). Where indicated,
a second osmotic lysis step was performed by resuspending the P
 
200
 
 frac-
tion in 20 mM K-Pipes, pH 6.8 (PS0), and separating the S
 
0
 
 and P
 
0
 
 frac-
tions by centrifugation at 10,000 
 
g
 
 for 5 min.
 
Subvacuolar Vesicle Isolation
 
Vacuoles were isolated from 700–800 OD
 
600
 
 U of spheroplasts prepared
from the 
 
cvt17
 
 strain. Differential lysis was performed in PS200 containing
1 mM Pefabloc and 2 
 
m
 
g/ml pepstatin A, and the resulting P
 
200
 
 fraction
was resuspended in 3 ml of 12% Ficoll. This was overlaid with 3 ml of 10%
Ficoll, 3 ml of 4% Ficoll, and 1 ml of PS200. All Ficoll solutions were
made in PS200 with protease inhibitors. Vacuoles were isolated from the
4% Ficoll/PS200 interface after centrifugation at 100,000 
 
g
 
 for 90 min at
8
 
8
 
C. The vacuoles were diluted with 2 vol of PS200 and collected by cen-
trifugation at 60,000 
 
g
 
 for 15 min. An aliquot of the vacuole fraction was
saved for analysis. The remaining vacuoles were resuspended in 200 
 
m
 
l
PS0 containing protease inhibitors and loaded on top of an Optiprep step
gradient consisting of 500 
 
m
 
l of 37% Optiprep in PS0 (density 1.12) over-
laid with 1.3 ml of 19% Optiprep in PS0 (density 1.06). The resulting step
gradient was subjected to centrifugation at 160,000 
 
g
 
 for 60 min at 12
 
8
 
C.
Four fractions were collected: the PS0/1.06 interface (vacuolar vesicles
[VV]), an equal aliquot of the 1.06 density region (low density [LD]), the
1.06/1.12 interface (subvacuolar vesicles [SV]), and the 1.12 density region
(high density [HD]).
 
Vacuole Isolation
 
Vacuoles were isolated from small scale preparations for the experiments
in Figs. 2 and 3. Spheroplasts (50 OD
 
600
 
 U) were lysed in PS200 buffer and
centrifuged at 5,000 
 
g
 
 for 5 min to generate the P
 
200
 
 fraction. This fraction
was resuspended in 900 
 
m
 
l 10% Ficoll, and then overlaid with 1 ml 4% Fi-
coll and 200 
 
m
 
l PS200. The resulting step gradient was centrifuged at
166,000 
 
g
 
 for 60 min at 8
 
8
 
C. The vacuole fraction (V) was collected from
the 0/4 % Ficoll interface, the intermediate fraction (I) from the 4/10% Fi-
coll interface, and the pellet fraction (P) from the gradient pellet.
Protease treatment was with 50 
 
m
 
g/ml proteinase K for 15 min on ice.
Where indicated, Triton X-100 was added at a final concentration of 
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0.2%. Protease treatment results in the degradation of precursor API to
intermediate- and mature-sized bands; mature API is resistant to diges-
tion by proteinase K (Oda et al., 1996). Immunoblotting was performed as
before (Harding et al., 1996).
 
Immuno-EM 
 
Samples were prepared for immuno-EM as described (Baba et al., 1994)
with modifications. Cells were sandwiched between an aluminum and a
copper disk, frozen in liquid propane, and transferred to 0.1% formalde-
hyde in absolute acetone at 
 
2
 
80
 
8
 
C. After 1–2 d, they were transferred to
 
2
 
20
 
8
 
C, washed with absolute acetone, and then replaced stepwise with
cold absolute ethanol. LR white resin was applied and allowed to poly-
merize for 48 h with UV irradiation at 
 
2
 
20
 
8
 
C. Ultrathin sections were col-
lected onto Formvar-coated nickel grids, blocked with 2% BSA-PBS with
purified goat serum (1:50 dilution), and immunolabeled with affinity-puri-
fied API antibody by floating the grids on a 1:200 or 1:500 dilution of anti-
serum for 1 h at room temperature. The grids were then washed, incu-
bated with 10 nm gold–conjugated goat anti–rabbit IgG, washed again,
and then fixed with 1% glutaraldehyde for 3 min. Sections were stained
for 7 min with 4% uranyl acetate and with 0.2% lead citrate for 30 s, and
then examined with an electron microscope (H-800; Hitachi Ltd., Tokyo,
Japan) at 125 kV.
 
Results
 
API Maturation Is Severely Inhibited by
Low Temperatures
 
One way to distinguish between membrane translocation
through a proteinaceous channel and vesicular transport
reactions is by sensitivity to low temperature. For exam-
ple, at 10
 
8
 
C translocation of CPY into the ER lumen oc-
curs efficiently, while the packaging and transport of CPY
from the ER to the Golgi (a vesicular process) is blocked
(Baker and Schekman, 1989). We have previously shown
that API maturation in vitro is sensitive to low tempera-
ture (Scott and Klionsky, 1995). To examine the effect of
low temperature on the kinetics of API transport in cells,
pulse-chase experiments were performed at 10
 
8
 
, 14
 
8
 
, and
30
 
8
 
C. At 30
 
8
 
C API has a half-time for vacuolar delivery of
30–45 min (Klionsky et al., 1992); the reaction is essen-
tially complete after 2 h of chase (Fig. 1). However, at
10
 
8
 
C no mature API was detected, after incubation for 4 h
(Fig. 1). When CPY transport was also monitored in the
same samples, the ER form of CPY (p1CPY) accumu-
lated, indicating that membrane translocation into the ER
continued while vesicular reactions that carry cargo from
the ER to the Golgi were blocked (data not shown). When
the reactions were carried out at 14
 
8
 
C, a trace of mature
API was apparent at the 4-h chase point, indicating that
even at this intermediate temperature API delivery is se-
verely inhibited. This requirement for relatively high tem-
peratures is typical of vesicle-mediated transport but not
membrane translocation through a proteinaceous channel.
 
Identification of Prevacuolar API-containing Vesicles
 
If API is transported to the vacuole by a vesicular interme-
diate, it may require some of the same components as the
vacuolar protein sorting (Vps) pathway for correct com-
partment identification, docking, or fusion. Similarly, if API-
containing vesicles fuse at the endosome or late endosome
instead of at the vacuole, then proteins that are required
for late steps in the Vps pathway would also be required
for API targeting. Previously, we examined 
 
vps
 
 mutants
for their API phenotype. The 
 
vps
 
 mutants display differ-
ential effects on API processing; some 
 
vps
 
 mutants are es-
sentially wild type for API transport, while others are
strongly blocked (Klionsky et al., 1992; Scott and Klion-
sky, 1995). To reduce the possibility of secondary defects
and to allow a more direct assessment of the role of a 
 
vps
 
gene product in API import, we examined API delivery in
a 
 
vps18
 
 temperature-conditional mutant.
 
vps18
 
D
 
 cells containing a temperature-sensitive allele of
 
vps18
 
 on a plasmid were subjected to pulse-chase experi-
ments at the permissive and nonpermissive temperatures.
The 
 
vps18
 
 strain was completely blocked for API delivery
at the nonpermissive temperature (Fig. 2 
 
A
 
). Previous
studies of Vps18p (Pep3p) suggest that it is involved in
transport between the endosome and the vacuole (Robin-
son et al., 1991), and that it may be located on the vacuolar
membrane surface (Preston et al., 1991). The fact that API
transport is tightly blocked in this mutant suggests that
API-containing vesicles may either join vacuole-destined
proteins somewhere within the endosomal system, or may
use some of the same molecular components used by vesi-
cles traveling from the endosome to the vacuole to fuse at
the vacuolar membrane.
To determine the step in the API transport pathway that
is affected by 
 
vps18
 
, subcellular fractionation experiments
were performed. Spheroplasts were pulse labeled and lysed
in PS0, a buffer of low osmotic strength that lyses both the
plasma membrane and the vacuole membrane, while
smaller vesicles remain intact (see Fig. 4). After a 5-min
pulse at the nonpermissive temperature, the majority of
prAPI remained in the supernatant fraction and was sensi-
tive to added protease, consistent with a cytosolic localiza-
tion (Fig. 2 
 
B
 
). After 60 min of chase, a fraction of prAPI
was contained in the pellet fraction and was protease pro-
tected after lysis in PS0 buffer. Since this treatment lyses
both the plasma membrane and the vacuole, this result
suggests that prAPI is trapped in a prevacuolar vesicular
compartment.
To confirm that the population of prAPI contained
within the pellet fraction is not within the vacuole, further
fractionation experiments were performed. These experi-
ments were carried out using a differential lysis technique
based on resuspension of spheroplasts in PS200 buffer.
Figure 1. API delivery is blocked at low temperatures. SEY6210
cells were pulse labeled for 5 min and chased for the times indi-
cated. Identical experiments were performed at 108, 148, and
308C. API was recovered by immunoprecipitation followed by
SDS-PAGE and detected by a STORM phosphorimager (Molec-
ular Dynamics, Sunnyvale, CA). The positions of prAPI and
mAPI are indicated. 
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Marker protein analysis shows that this treatment lyses the
plasma membrane, while maintaining the integrity of the
majority of vacuoles (Harding et al., 1996, 1995). Cells
containing the 
 
vps18
 
 mutation were pulse labeled for 10
min, and then chased for 10 min at the permissive temper-
ature before shifting to the nonpermissive temperature for
60 min. This pulse-chase regime allowed for transport of
CPY to the vacuole to occur before the onset of the 
 
vps18
 
block. Since delivery of API is slower than CPY, matura-
tion of API was still prevented. As in the PS0 buffer, a
population of prAPI was maintained in the pellet fraction
after lysis in PS
 
200
 
 buffer. Vacuoles were then isolated
from the P
 
200
 
 fraction by flotation through 4% Ficoll. Af-
ter this treatment, mCPY was recovered in the vacuole
fraction, while trapped p2CPY was recovered in the gradi-
ent pellet. In the same samples, none of the trapped prAPI
was collected in the vacuole fraction (Fig. 2 
 
C
 
). These re-
sults indicate that the 
 
vps18
 
 block causes the accumulation
of prAPI in a nonvacuolar compartment, and suggest that
API may be transported to the vacuole via a vesicular in-
termediate.
 
A Targeting Mutant in the API Propeptide Accumulates 
in a Nonvacuolar Compartment
 
To extend our analysis of the cytoplasmic intermediate
compartment, we examined the location of API with a mu-
tation in the propeptide region. Mutations in the API pro-
region interfere with the membrane binding or subsequent
steps of the transport process. In particular, changing pro-
line 22 to leucine (P22L) causes prAPI to accumulate in a
membrane-bound state that undergoes further transport
at a very minimal rate (Oda et al., 1996). This mutation is
predicted to disrupt a 
 
b
 
 turn separating two 
 
a
 
 helices that
make up the API propeptide and results in a mutant pro-
tein with increased membrane affinity compared with the
wild-type protein (Oda et al., 1996). Differential lysis frac-
tionation experiments were performed in PS200 buffer us-
ing cells containing P22L API. P22L API was primarily
precursor sized, but it was recovered in the membrane pel-
let fraction where it was protease sensitive, indicating that,
although it is membrane bound, it is not compartmental-
ized (Fig. 3 
 
A
 
). Under these same conditions, wild-type
precursor is located exclusively in the supernatant fraction
(Harding et al., 1995, 1996). Vacuoles were then isolated
from the pellet containing P22L API. As was the case with
the trapped prAPI in the 
 
vps18 mutant strain, precursor
P22L API did not cofractionate with vacuolar markers
such as PrA, but was instead recovered from the gradient
pellet (Fig. 3 B), suggesting that prAPI is first localized to
a nonvacuolar membrane.
Since P22L API is transport defective (Oda et al., 1996),
it is possible that prAPI that accumulates in this mutant
may not be on the correct transport pathway. To examine
this question, the severity of the P22L defect was followed
by pulse-chase analysis. P22L API-containing cells were
pulse labeled for 5 min, and then subjected to a nonradio-
active chase reaction in either nitrogen-containing or ni-
trogen starvation medium. Nitrogen starvation increases
the capacity of the API transport machinery in wild-type
cells (Scott et al., 1996). In nitrogen-containing medium,
the transport of P22L API is slow but not completely de-
fective. However, when the chase was performed in SD-N,
the import efficiency was significantly improved (Fig. 3 C).
The rate of API delivery in this experiment is too rapid to
be explained by bulk autophagy alone. These results indi-
cate that the deficiency of P22L API can be overcome in
conditions where the capacity for API transport is in-
creased, suggesting that the defective API is maintained
on the import pathway.
Identification and Purification of Subvacuolar Vesicles 
Containing API
Genetic and phenotypic analyses indicate that the majority
of the cvt, apg, and aut mutants are defective in both API
maturation and autophagy (Harding et al., 1996; Scott et al.,
1996). Our results with vps18 and P22L API suggested that
API enters a cytoplasmic vesicle. If API uses the same
machinery as that used by the autophagic pathway, the cy-
toplasmic intermediate compartment may be an autopha-
gosome (Baba et al., 1994, 1995). Autophagosomes are dou-
Figure 2. Precursor API is trapped in a prevacuolar compartment
in  vps18 cells. (A) Yeast strain JSR18D1 with plasmid pJSR9
(vps18 ts) was grown at the permissive temperature of 268C. Be-
fore labeling, the cells were incubated at either 268 or 388C for 10
min. Pulse labeling was for 5 min, followed by the indicated chase
times. (B) vps18 spheroplasts were shifted to 388C for 5 min,
pulse labeled for 5 min, and then chased for either 0 or 60 min. At
each time point the spheroplasts were collected by centrifugation
and resuspended in PS0 buffer. The Total (T) fraction either re-
ceived no treatment, was treated with 50 mg/ml proteinase K, or
received proteinase K in the presence of 0.2% Triton X-100. The
supernatant (S0) and pellet (P0) fractions were collected after
centrifugation at 10,000 g for 5 min. (C) vps18 spheroplasts were
pulse labeled for 10 min, chased for 10 min at 268C, and then
shifted to 388C and chased for an additional 60 min. These cells
were then lysed in PS200 buffer, and the S200 and P200 fractions
were collected by centrifugation at 5,000 g for 5 min. The P200
fraction was resuspended in 10% Ficoll solution made in PS200,
and vacuoles were isolated by flotation through 4% Ficoll. V,
vacuole fraction; I, 4/10% Ficoll interface fraction; P, gradient
pellet. Proteins of interest were recovered by immunoprecipita-
tion, followed by SDS-PAGE, and detected by a Molecular Dy-
namics STORM phosphorimager. The positions of precursor and
mature API and CPY are indicated.Scott et al. Cytoplasm to Vacuole Protein Import Is Vesicular 41
ble-membraned structures that fuse with the vacuole,
resulting in the release of a subvacuolar single-membraned
vesicle termed an autophagic body (Takeshige et al., 1992;
Baba et al., 1994). This vesicle is subsequently degraded in
a PrB-dependent manner. Accordingly, mutations in ei-
ther PrA or PrB cause the accumulation of autophagic
bodies inside the vacuole (Takeshige et al., 1992), as well
as causing a processing defect in API (Klionsky et al., 1992).
Lack of API maturation in pep4 or prb1 mutant strains
could be the result of a direct processing block and/or inac-
cessibility of precursor API that is contained within intact
subvacuolar vesicles. To investigate whether API can be
trapped within a subvacuolar vesicle, additional fraction-
ation studies were performed using the cvt17 mutant. Like
PrA and PrB mutants, cvt17 also accumulates autophagic
bodies in the vacuole (Harding et al., 1996) but has the ad-
ditional advantage that it is not defective in PrA, so that this
protein can be used as a marker protein for the vacuolar
lumen.
When cvt17 cells were subjected to differential osmotic
lysis in PS200 buffer, the majority of prAPI and PrA was
maintained within the pellet fraction (Fig. 4 A), while cy-
tosolic proteins such as PGK were released into the super-
natant fraction (data not shown). The prAPI in these cells
was protease protected, indicating its localization to a
membrane-enclosed compartment (Fig. 4 A). Additional
fractionation experiments were performed to determine
whether this population of API was localized in the vacu-
olar lumen or in a separate protease-protected compart-
ment.
For these studies, cvt17 spheroplasts were resuspended
first in PS200 to lyse the plasma membrane while main-
taining vacuolar integrity. After separating the cytosolic
fraction from the vacuole-containing pellet fraction by
centrifugation, the resulting pellet (P200) was subjected to a
second lysis step with a very low osmotic strength buffer
(PS0). After separation by centrifugation at 10,000 g, this
second lysis step resulted in the S0 and P0 fractions. While
the majority of the vacuolar lumen marker PrA was recov-
ered in the P200 fraction, it was released into the S0 fraction
upon resuspension in PS0, indicating vacuolar lysis. How-
ever, a considerable amount of prAPI is still maintained
within the pellet fraction, indicating that it is not free in
the vacuolar lumen (Fig. 4 B). The pelletable prAPI is re-
leased into a soluble fraction by treatment with Triton
X-100, indicating that it is enclosed within a membrane
rather than an aggregate (data not shown). In addition,
prAPI is collected in the pellet fraction by the relatively
low force of centrifugation at 10,000 g, consistent with its
association with a large compartment such as an auto-
phagic body. Microscopy studies indicate that autophagic
bodies are z 300–900 nm in diam (Baba et al., 1994, 1995),
much larger than secretory vesicles that exist in 50- and
100-nm classes (Novick et al., 1980).
The S0 and P0 fractions were subjected to protease treat-
ment with proteinase K. The prAPI that was released into
Figure 3. A mutant in the
API propeptide causes accu-
mulation of prAPI on a non-
vacuolar compartment. (A)
Spheroplasts from an ape1D
strain containing a plasmid
bearing P22L API were sub-
jected to differential lysis in
PS200 buffer. The Total (T)
fraction (after differential ly-
sis) either received no treat-
ment, was treated with 50 mg/
ml proteinase K, or received
proteinase K in the presence
of 0.2% Triton X-100. (B)
The supernatant (S200) and
pellet (P200) fractions were
collected after centrifuga-
tion at 5,000 g for 5 min. The P200 fraction was resuspended in 10% Ficoll, and vacuoles were isolated by flotation through 4% Ficoll.
V, vacuole; I, 4/10% Ficoll interface; P, gradient pellet. Proteins were detected by Western blotting. The positions of prAPI, mAPI, and
mPrA are indicated. (C) ape1D cells containing P22L API on a plasmid were pulse labeled for 5 min, harvested by centrifugation, and
subjected to a nonradioactive chase in either nitrogen-containing (SMD) or nitrogen starvation (SD-N) medium. Samples were col-
lected at the times indicated and immunoprecipitated with API antiserum. The resulting SDS-PAGE gels were quantified using a Mo-
lecular Dynamics STORM phosphorimager.
Figure 4. Precursor API is trapped within a vesicle in cvt17 mu-
tants. (A) Precursor API is in a protease-protected compartment
in cvt17 mutants. THY32 (cvt17) spheroplasts were subjected to
differential lysis and protease treatment in PS200 buffer as in Fig
3. (B) Precursor API is not free in the vacuolar lumen in cvt17
mutants. Differential fractionation was continued by resuspend-
ing the P200 fraction in PS0 buffer and separating the supernatant
(S0) and pellet (P0) fractions by centrifugation at 10,000 g. The S0
and P0 fractions were treated with proteinase K in the presence
and absence of Triton X-100 as indicated. All fractions were pre-
cipitated with 10% TCA and resolved by SDS PAGE; proteins of
interest were detected by Western blotting. The positions of
prAPI, mAPI, and mPrA are indicated.The Journal of Cell Biology, Volume 138, 1997 42
the S0 fraction was digested to the mature size, while
prAPI in the P0 fraction was protease protected unless
membranes were solubilized by the addition of detergent
(Fig. 4 B), suggesting that the prAPI in the P0 fraction re-
mains in a vesicular compartment. This result, together
with the fact that the prAPI is in a less osmotically sensi-
tive compartment than the vacuolar lumen, suggests that it
may instead be within a subvacuolar vesicle such as the au-
tophagic bodies previously identified microscopically.
Purification of Subvacuolar Vesicles from cvt17 Cells
Since purified vacuoles contain little contamination from
other organelles, we used isolated vacuoles from cvt17
cells as the starting material for purification of prAPI-con-
taining subvacuolar vesicles. Isolated vacuoles were per-
meabilized by resuspension in PS0 buffer to release API-
containing vesicles. Optiprep step gradients were then
used to separate the released subvacuolar vesicles from re-
maining vacuolar membranes, which may reseal into vesi-
cles after lysis and release of luminal contents. Appropriate
densities for separation of these two vesicle populations in
our buffer system were determined empirically.
We found that vacuolar vesicles are unable to enter an
Optiprep solution with a density of 1.06, while some of the
prAPI-containing subvacuolar vesicles sediment through
the 1.06 density step and become concentrated at the 1.06/
1.12 interface (Fig. 5 A). The majority of vacuolar mem-
branes in this gradient, marked by ALP, is in the VV frac-
tion collected from the 0/1.06 density interface. This is in
contrast with prAPI, which is localized in both the VV
fraction and the SV fraction (the 0/1.06 and the 1.06/1.12
density interfaces). A portion of the VV fraction and the
SV fraction was subjected to protease treatment. Precur-
sor API in both fractions was protease protected in the ab-
sence of detergent, indicating that it is still localized within
a membrane-bound compartment (Fig. 5 B). ALP con-
tained in the VV fraction was digested to a slightly lower
molecular weight form both in the presence and absence
of detergent. As ALP is a type II transmembrane protein
that contains a cytosolic domain (Klionsky and Emr, 1989),
this is the expected result, indicating that the added pro-
tease is working efficiently.
API-containing Vesicles Can Be Detected
by Immuno-EM
To provide additional evidence for a vesicular mode of
API transport, cells were examined using immuno-EM with
antibodies against API. Wild-type and cvt17 cells were grown
in YPD to late log phase, harvested, and rapidly frozen.
When wild-type cells were probed with preimmune serum,
or ape1D cells were probed with API antiserum, no immu-
nogold signal was detected (data not shown). Wild-type
cells probed with API antiserum contained dispersed gold
particles in the vacuole lumen, confirming that mature
API is a soluble luminal hydrolyase and indicating that
API itself does not appear to aggregate, despite its dodeca-
meric structure (Fig. 6 A). When sections from cvt17 cells
were examined, both cytosolic and subvacuolar API-con-
taining vesicles were evident (Fig 6, B and C). The cyto-
solic vesicles appeared near the surface of the vacuole.
These are most likely double-membraned vesicles that are
approaching the vacuole surface for docking and fusion.
Subvacuolar vesicles were detected in cvt17 cells, but not
in wild-type cells, confirming that the accumulation of
these vesicles is the result of mutation in the CVT17 gene.
Characterization of prAPI-containing Vesicles
Additional analysis of the subvacuolar vesicles isolated
from cvt17 cells was performed to evaluate the degree of
purity attained by this fractionation procedure. After dif-
ferential osmotic lysis and recovery on Optiprep step gra-
dients, fractions were analyzed by immunoblot analysis
with antibodies against marker proteins for various yeast
organellar compartments. As in the experiment shown in
Fig. 5, the SV fraction was nearly devoid of PrA and ALP,
but still contained prAPI (Fig. 7 A). When these same
fractions were probed with antibodies raised against Kex2p,
a Golgi-resident protein (Redding et al., 1991), it was only
detected in the total fraction. Similarly, Sec13p, a compo-
nent of COPII-coated secretory vesicles (Barlowe et al.,
1994), was primarily detected in the total fraction. In addi-
tion, components of the coatomer complex were detected
in the total fraction, but not in the VV and SV fractions (data
not shown). Sec61p, an ER membrane protein (Stirling et al.,
1992), was found in all of the recovered fractions. Sec61p
is not enriched in the vacuole fraction when compared
with the total fraction, however, suggesting that it is con-
taminating this preparation, rather than specifically puri-
fied. The cytosolic marker protein PGK also contaminates
the vacuole and subvacuolar fractions to a certain degree,
but is not specifically enriched. These fractions were also
examined by staining with SYPRO orange. The protein
profiles of the vacuolar vesicle and subvacuolar vesicle
fractions were clearly distinct. A number of proteins ap-
peared specifically enriched in the subvacuolar vesicle
fraction (Fig. 7 B). 
Discussion
Recent evidence that the majority of mutants in the au-
tophagy and Cvt pathways display the same phenotypes
Figure 5. Precursor API is contained within subvacuolar vesicles
in cvt17 mutants. (A) Isolated vacuoles (V) from cvt17 cells were
lysed in PS0 buffer, loaded on top of an Optiprep step gradient,
and centrifuged at 170,000 g for 60 min as described in Materials
and Methods. Fractions VV, 0/1.06 interface; LD, 1.06 region; SV,
1.06/1.12 interface; HD, 1.12 region. (B) An aliquot of fractions
VV and SV was treated with proteinase K either in the presence
or absence of Triton X-100 as indicated. Because of the presence
of protease inhibitors in the vesicle isolation procedure, an inter-
mediate-sized API degradation product results from proteinase
K treatment. The V fraction represents one-tenth of the load of
the Optiprep gradient. Proteins were detected by Western blot-
ting. The positions of prAPI and mALP are indicated.Scott et al. Cytoplasm to Vacuole Protein Import Is Vesicular 43
suggested that API transport is vesicle mediated (Harding
et al., 1996; Scott et al., 1996). Additionally, studies of the
oligomeric state of API during transit indicate that this
protein is assembled into a dodecamer in the cytosol be-
fore transport (Kim et al., 1997). These results, coupled with
the fact that API transport is extremely sensitive to low
temperatures (Fig. 1) and requires a GTP-binding protein
(Scott and Klionsky, 1995), indicated that the Cvt pathway
may be vesicular. In this report we demonstrate biochemi-
cally and morphologically that prAPI is transported by a
vesicle-mediated process.
We performed fractionation analysis on various protein
targeting mutants to identify those that might accumulate
transport intermediates on the API targeting pathway. Ex-
amination of prAPI that accumulates in the vps18 mutant
revealed that a population of prAPI is trapped in a nonvac-
uolar vesicular compartment in this strain (Fig. 2). Although
the precise role of Vps18p is not known, it is involved at a
late step in vacuolar protein sorting, presumably after the
endosome (Preston et al., 1991; Robinson et al., 1991).
This result, together with the fact that the P22L API mu-
tant accumulates on a nonvacuolar membrane (Fig. 3), in-
dicates that prAPI first binds and then becomes encapsu-
lated in a vesicle before delivery to the vacuole. These
results are supported by immunoelectron microscope
analysis, which indicates the presence of API-containing
vesicles in the cytosol (Fig. 6 B).
Figure 6. Immuno-EM of cvt17 cells. Yeast strains SEY6210 (pa-
rental wild type) and THY32 (cvt17) were grown in YPD and
prepared for microscopy as described in Materials and Methods.
(A) Wild-type cells probed with antibody against mature API.
(B) A cvt17 section showing a cytosolic vesicle containing prAPI
probed with antibody against the API proregion. (C) A cvt17 sec-
tion showing subvacuolar vesicles containing API probed with
antibody against mature API. N, nucleus; V, vacuole; (arrows)
API containing vesicles. Bars, 0.5 mm.
Figure 7. Characterization of API-containing vesicles. (A) Frac-
tionations were performed as in Fig. 5. The total (T), vacuole (V),
vacuolar vesicle (VV), and subvacuolar vesicle (SV) fractions are
shown. Proteins were detected by immunoblotting as indicated in
the figure. (B) SYPRO orange staining detected by fluorescent
scanning mode on a Molecular Dynamics STORM phosphorim-
ager. The relative mobility of the molecular mass standards are
indicated on the left. Polypeptides enriched in the subvacuolar
vesicles are indicated on the right.The Journal of Cell Biology, Volume 138, 1997 44
We predicted that, analogous to macroautophagy, API
is transported inside double-membraned vesicles (autopha-
gosomes) that are formed in the cytosol. The autophago-
somes would be subsequently targeted to the vacuole
where the outer membrane would fuse with the vacuolar
membrane, releasing the inner vesicle (autophagic body)
into the vacuolar lumen. This hypothesis is supported by
subcellular fractionation experiments using cvt17 that dem-
onstrate the presence of API-containing subvacuolar trans-
port vesicles (Figs. 4 and 5). In addition, immuno-EM of
cvt17 confirmed the presence of API-containing subvacu-
olar vesicles (Fig. 6). Purification and characterization of
the complement of proteins contained in this compart-
ment suggest that proteins unique from those of the vacu-
ole make up these subvacuolar transport vesicles (Fig. 7).
Together, these data indicate that API is constitutively
packaged into cytosolic vesicles that are then transported
to the vacuole. These vesicles could either be targeted di-
rectly to the vacuole, or could first fuse with an endosomal
compartment. In the event that they fuse at the vacuole,
they may use common recognition and fusion components
such as a vacuolar t-SNARE and v-SNARE, as well as the
sec17/sec18 complex, to facilitate this reaction. If fusion in-
stead occurs at the endosome, then all of the components
necessary for late steps in vacuolar targeting or maturation
would be required for vacuolar delivery. This is similar to
the situation that has been proposed in mammalian cells,
where lysosomes develop through the fusion of various
different classes of endosomal compartments (Dunn, 1995).
Possibly the yeast endosomal system operates similarly:
autophagic vesicles and secretory vesicles carrying vacu-
ole-destined cargo could both fuse and deliver their con-
tents to the endosome. Through continued fusion reactions,
this compartment could develop into an enzymatically ma-
ture vacuole. Further studies will provide information on
the mechanism of API import and in particular the stage
at which it integrates with vacuolar delivery through the
secretory pathway and endosomal systems.
These results clearly demonstrate that API transport is a
vesicular process that has many similarities to the degrada-
tive macroautophagic pathway. Despite this evidence, the
relationship between the constitutive API delivery path-
way and macroautophagy remains unclear. In addition,
many uncertainties remain regarding protein trafficking
by autophagic vesicles. These include such basic mechanis-
tic questions as the membrane of origin of autophagic ves-
icles and what triggers the formation, movement, fusion, and,
finally, breakdown of these transport vesicles. The avail-
ability of purified vesicular compartments and the use of API
as a marker protein will be valuable tools for these studies.
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